A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma

Pediatric Blood and Cancer

Volumn 63, Issue 8, 2016, Pages 1349-1356

  Villablanca, Judith G ^a   Volchenboum, Samuel L ^b   Cho, Hwangeui ^c   Kang, Min H ^c   Cohn, Susan L ^b   Anderson, Clarke P ^d   Marachelian, Araz ^a   Groshen, Susan ^e   Tsao Wei, Denice ^e   Matthay, Katherine K ^f   Maris, John M ^g   Hasenauer, Charlotte E ^a   Czarnecki, Scarlett ^a   Lai, Hollie ^a   Goodarzian, Fariba ^a   Shimada, Hiro ^a   Reynolds, Charles Patrick ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

buthionine sulfoximine; melphalan; neuroblastoma; Phase 1; transplant

Indexed keywords

BUTHIONINE SULFOXIMINE; FILGRASTIM; MELPHALAN; TROPONIN;

ABDOMINAL PAIN; ADOLESCENT; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTEREMIA; BLOODSTREAM INFECTION; CANCER RECURRENCE; CARDIOPULMONARY ARREST; CATHETER INFECTION; CELLULITIS; CHILD; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG DOSE ESCALATION; DRUG TOLERABILITY; EVENT FREE SURVIVAL; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; HEART LEFT VENTRICLE FAILURE; HERPES SIMPLEX; HIGH RISK PATIENT; HUMAN; HYPERTRANSAMINASEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOTENSION; HYPOXIA; LUNG DISEASE; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MOUTH INFECTION; MOUTH PAIN; MUCOSA INFLAMMATION; NAUSEA; NEUROBLASTOMA; OVERALL SURVIVAL; PHARYNGITIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTHROMBIN TIME; RESPIRATORY TRACT INFECTION; SIDE EFFECT; SINUSITIS; SKIN INFECTION; STOMATITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT INFECTION; VOLUME OF DISTRIBUTION; VOMITING;

EID: 84976521096     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25994     Document Type: Article

References (46)

1. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, Gerbing RB, London WB, Villablanca JG. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A Children's Oncology Group study. J Clin Oncol 2009;27:1007–1013.
2. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010;363:1324–1334.
3. Dini G, Lanino E, Garaventa A, Rogers D, Dallorso S, Viscoli C, Castagnola E, Manno G, Brisigotti M, Rosanda C. Myeloablative therapy and unpurged autologous bone marrow transplantation for poor-prognosis neuroblastoma: Report of 34 cases. J Clin Oncol 1991;9:962–969.
4. Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, Laquaglia MP, Yu AL, Diller L, Buxton A, Park JR, Cohn SL, Maris JM, Reynolds CP, Villablanca JG. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): A randomised phase 3 trial. Lancet Oncol 2013;14:999–1008.
5. Pritchard J, Cotterill SJ, Germond SM, Imeson J, de Kraker J, Jones DR. High dose melphalan in the treatment of advanced neuroblastoma: Results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer 2005;44:348–357.
6. Suzukake K, Vistica BP, Vistica DT. Dechlorination of L-phenylalanine mustard by sensitive and resistant tumor cells and its relationship to intracellular glutathione content. Biochem Pharmacol 1983;32:165–167.
7. Suzukake K, Petro BJ, Vistica DT. Reduction in glutathione content of L-PAM resistant L1210 cells confers drug sensitivity. Biochem Pharmacol 1982;31:121–124.
8. Fahey RC, Sundquist AR. Evolution of glutathione metabolism. Adv Enzymol Relat Areas Mol Biol 1991;64:1–53.
9. Griffith OW, Meister A. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem 1979;254:7558–7560.
10. Griffith OW, Anderson ME, Meister A. Inhibition of glutathione biosynthesis by prothionine sulfoximine (S-n-propyl homocysteine sulfoximine), a selective inhibitor of gamma-glutamylcysteine synthetase. J Biol Chem 1979;254:1205–1210.
11. Griffith OW. Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis. J Biol Chem 1982;257:13704–13712.
12. Somfai Relle S, Suzukake K, Vistica BP, Vistica DT. Reduction in cellular glutathione by buthionine sulfoximine and sensitization of murine tumor cells resistant to L-phenylalanine mustard. Biochem Pharmacol 1984;33:485–490.
13. Green JA, Vistica DT, Young RC, Hamilton TC, Rogan AM, Ozols RF. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res 1984;44:5427–5431.
14. Hamilton TC, Winker MA, Louie KG, Batist G, Behrens BC, Tsuruo T, Grotzinger KR, McKoy WM, Young RC, Ozols RF. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol 1985;34:2583–2586.
15. Louie KG, Behrens BC, Kinsella TJ, Hamilton TC, Grotzinger KR, McKoy WM, Winker MA, Ozols RF. Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res 1985;45:2110–2115.
16. Ozols RF, Louie KG, Plowman J, Behrens BC, Fine RL, Dykes D, Hamilton TC. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione. Biochem Pharmacol 1987;36:147–153.
17. Ongaro A, Pellati A, De Mattei M, De Terlizzi F, Rossi CR, Campana LG. Enhancement of melphalan activity by buthionine sulfoximine and electroporation in melanoma cells. Anticancer Drugs 2015;26:284–292.
18. Anderson CP, Seeger RC, Statake N, Monforte-Munoz HL, Keshelava N, Bailey HH, Reynolds CP. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line. J Pediatr Hematol Oncol 2001;23:500–505.
19. Anderson CP, Reynolds CP. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy. Bone Marrow Transplant 2002;30:135–140.
20. Anderson CP, Tsai JM, Meek WE, Liu RM, Tang Y, Forman HJ, Reynolds CP. Depletion of glutathione by buthionine sulfoxine is cytotoxic for human neuroblastoma cell lines via apoptosis. Exp Cell Res 1999;246:183–192.
21. Anderson CP, Tsai J, Chan W, Park CK, Tian L, Lui RM, Forman HJ, Reynolds CP. Buthionine sulphoximine alone and in combination with melphalan (L-PAM) is highly cytotoxic for human neuroblastoma cell lines. Eur J Cancer 1997;33:2016–2019.
22. Jordan J, d'Arcy Doherty M, Cohen GM. Effects of glutathione depletion on the cytotoxicity of agents toward a human colonic tumour cell line. Br J Cancer 1987;55:627–631.
23. Siemann DW, Beyers KL. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy. Br J Cancer 1993;68:1071–1079.
24. Prezioso JA, Fitzgerald GB, Wick MM. Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan. J Invest Dermatol 1992;99:289–293.
25. Prezioso JA, Fitzgerald GB, Wick MM. Effects of tyrosinase activity on the cytotoxicity of 3,4- dihydroxybenzylamine and buthionine sulfoximine in human melanoma cells. Pigment Cell Res 1990;3:49–54.
26. Yang B, Keshelava N, Anderson CP, Reynolds CP. Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine. Cancer Res 2003;63:1520–1526.
27. Sheard MA, Ghent MV, Cabral DJ, Lee JC, Khankaldyyan V, Ji L, Wu SQ, Kang MH, Sposto R, Asgharzadeh S, Reynolds CP. Preservation of high glycolytic phenotype by establishing new acute lymphoblastic leukemia cell lines at physiologic oxygen concentration. Exp Cell Res 2015;334:78–89.
28. Friedman HS, Colvin OM, Griffith OW, Lippitz B, Elion GB, Schold SCJ, Hilton J, Bigner DD. Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoximine-mediated glutathione depletion. J Natl Cancer Inst 1989;81:524–527.
29. Skapek SX, VanDellen AF, McMahon DP, Postels DG, Griffith OW, Bigner DD, Friedman HS. Melphalan-induced toxicity in nude mice following pretreatment with buthionine sulfoximine. Cancer Chemother Pharmacol 1991;28:15–21.
30. Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M, Spriggs DR. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: An attempt at modulation of glutathione. J Clin Oncol 1994;12:194–205.
31. O'Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T, Brennan J, Bookman MA, Hoffman J, Young RC, Comis RL, Ozols RF. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol 1996;14:249–256.
32. Bailey HH, Ripple G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Mahvi D, Schink J, Pomplun M, Mulcahy RT, Wilding G. Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. J Natl Cancer Inst 1997;89:1789–1796.
33. Anderson CP, Matthay K, Perentesis J, Neglia JP, Bailey HH, Villablanca JG, Groshen S, Hasenauer B, Maris JM, Seeger RC, Reynolds CP. Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma. Pediatr Blood Cancer 2015;62:1739–1746.
34. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009;101:708–720.
35. Yanik GA, Villablanca JG, Maris JM, Weiss B, Groshen S, Marachelian A, Park JR, Tsao-Wei D, Hawkins R, Shulkin BL, Jackson H, Goodarzian F, Shimada H, Courtier J, Hutchinson R, Haas-Kogan D, Hasenauer CB, Czarnecki S, Katzenstein HM, Matthay KK. 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A New Approaches to Neuroblastoma Therapy (NANT) phase II study. Biol Blood Marrow Transplant 2015;21:673–681.
36. Messina JA, Cheng S-C, Franc BL, Charron M, Shulkin B, To B, Maris JM, Yanik G, Hawkins RA, Matthay KK. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer 2006;47:865–874.
37. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–216.
38. Nath CE, Shaw PJ, Montgomery K, Earl JW. Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients. Br J Clin Pharmacol 2007;64:151–164.
39. Nath CE, Shaw PJ, Montgomery K, Earl JW. Melphalan pharmacokinetics in children with malignant disease: Influence of body weight, renal function, carboplatin therapy and total body irradiation. Br J Clin Pharmacol 2005;59:314–324.
40. Tranchand B, Ploin YD, Minuit MP, Sapet C, Biron P, Philip T, Ardiet C. High-dose melphalan dosage adjustment: Possibility of using a test-dose. Cancer Chemother Pharmacol 1989;23:95–100.
41. Ardiet C, Tranchand B, Biron P, Rebattu P, Philip T. Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Report in 26 cases. Cancer Chemother Pharmacol 1986;16:300–305.
42. Gouyette A, Hartmann O, Pico JL. Pharmacokinetics of high-dose melphalan in children and adults. Cancer Chemother Pharmacol 1986;16:184–189.
43. Bagatell R, London WB, Wagner LM, Voss SD, Stewart CF, Maris JM, Kretschmar C, Cohn SL. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: A Children's Oncology Group study. J Clin Oncol 2011;29:208–213.
44. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165–1173.
45. Ladenstein R, Poetschger U, Luksch R, Brock P, Castel V, Yaniv I, Papadakis V, Laureys G, Malis J, Balwierz W, Ruud E, Kogner P, Schroeder H, Forjaz De Lacerda A, Beck Popovic M, Bician P, Garami M, Trahair T, Pearson AD, Valteau Couanet D. Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial. J Clin Oncol 2011;29(Suppl 2):abstract 2.
46. Tagde A, Singh H, Kang MH, Reynolds CP. The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma. Blood Cancer J 2014;4:e229.